While investor caution is understandable given very cautious commentary from new management, our analysis of …
(Editor’s note: Corrected to show Chimerix’s stock offering involves existing shares ... It was unclear what drove the drop for Aegerion /quotes/zigman/624094 /quotes/nls/aegr AEGR, which plunged more than 10% to $76.42 at the close.
Aegerion Pharmaceuticals Inc. (NASDAQ: AEGR) engages in the development and commercialization ... Aegerion …
One name in particular that got drilled viciously was Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR). The company posted a huge earnings miss and offered less than stellar guidance. To make things worse, the company’s stock was …
Aegerion Pharmaceuticals (AEGR) was a big mover last session, as its shares rose over 5% on the day. The rise came on solid volume too with far more shares changing hands than in a normal session. This reverses the recent trend for the …
Aegerion Pharmaceuticals Inc. (NASDAQ: AEGR) should have a slogan that says “We love volatility.” The biotech stock now trades for just under $60 after its earnings report, but the 52-week trading range is $29.61 to $101.00. After a poor …
Aegerion did not reveal the terms of the offering in the filing, but said it had applied to list its stock on Nasdaq under the symbol “AEGR.” AEGR.O Our Standards:The Thomson Reuters Trust Principles.
AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, today announced that on October 1, 2014, Aegerion granted stock options to …
Several biopharmaceutical companies took it on the chin Wednesday, led by Aegerion Pharmaceuticals, which plunged on weak earnings and an analyst downgrade. Aegerion /quotes/zigman/624094/delayed /quotes/nls/aegr AEGR was off …